Skip to main content
SpringerLink
Log in

Inherited Breast Cancer

  • Chapter
Molecular Pathology in Clinical Practice

Abstract

Breast cancer is the most common cancer among women in Western countries, with about 180,000 new cases and 40,000 deaths occurring annually in the United States. Epidemiologic factors consistently associated with breast cancer risk include a family history of breast cancer, breast biopsy features, and hormonal risk factors such as age at menarche, parity, and age at first live birth. After female gender and age, family history of breast cancer is the most significant risk factor. In a meta-analysis of family history of breast cancer as a risk factor, the relative risk ranged from 1.5 for a second-degree relative to 3.6 for a mother and sister with breast cancer.1 Relative risks are significantly influenced by the degree of relationship of affected relatives and their age of breast cancer onset, with closer degrees of relationship and younger age of onset conveying higher risks. An analysis of family history as a risk factor using data from the Swedish Family-Cancer Database showed a populationattributable fraction of about 11%.2

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and metaanalysis. Int J Cancer. 1997;71:800–809.

    Article  PubMed  CAS  Google Scholar 

  2. Hemminki K, Granstrom C, Czene K. Attributable risks for familial breast cancer by proband status and morphology: a nationwide epidemiologic study from Sweden. Int J Cancer. 2002;100:214–219.

    Article  PubMed  CAS  Google Scholar 

  3. Offit K. Clinical Cancer Genetics. Risk Counseling and Management. New York: Wiley-Liss; 1998.

    Google Scholar 

  4. de Jong MM, Nolte IM, te Meerman GJ, et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet. 2002;39:225–242.

    Article  PubMed  Google Scholar 

  5. Meijers-Heijboer H, van den OA, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55–59.

    Article  PubMed  CAS  Google Scholar 

  6. Thorstenson YR, Roxas A, Kroiss R, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 2003;63:3325–3333.

    PubMed  CAS  Google Scholar 

  7. Kaklamani VG, Hou N, Bian Y, et al. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol. 2003;21:3236–3243.

    Article  PubMed  CAS  Google Scholar 

  8. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33–36.

    Article  PubMed  CAS  Google Scholar 

  9. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A. 1988;85:3044–3048.

    Article  PubMed  CAS  Google Scholar 

  10. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684–1689.

    Article  PubMed  CAS  Google Scholar 

  11. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.

    Article  PubMed  CAS  Google Scholar 

  12. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792.

    Article  PubMed  CAS  Google Scholar 

  13. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12:333–337.

    Article  PubMed  CAS  Google Scholar 

  14. Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays. 2000;22:728–737.

    Article  PubMed  CAS  Google Scholar 

  15. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408:429–432.

    Article  PubMed  CAS  Google Scholar 

  16. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–1490.

    Article  PubMed  CAS  Google Scholar 

  17. Byrne TJ, Reece MT, Adams LA, Hoffman DE, Lane MA, Cohn GM. A rapid immunoassay predicts BRCA1 and BRCA2 mutations in buccal cells. Oncol Rep. 2000;7:1203–1207.

    PubMed  CAS  Google Scholar 

  18. Byrne TJ, Reece MT, Adams LA, Lane MA, Cohn GM. An antibody assay predictive of BRCA1 mutations in ovarian tumors and normal tissue. Oncol Rep. 2000;7:949–953.

    PubMed  CAS  Google Scholar 

  19. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, hER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310–2318.

    Article  PubMed  CAS  Google Scholar 

  20. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539–548.

    Article  PubMed  CAS  Google Scholar 

  21. Van’ t Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536.

    Article  Google Scholar 

  22. Frank TS, manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16:2417–2425.

    PubMed  CAS  Google Scholar 

  23. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in doublestranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A. 1993;90:10325–10329.

    Article  PubMed  CAS  Google Scholar 

  24. van Orsouw NJ, Dhanda RK, Rines RD, et al. Rapid design of denaturing gradient-based two-dimensional electrophoretic gene mutational scanning tests. Nucleic Acids Res. 1998;26:2398–2406.

    Article  PubMed  Google Scholar 

  25. Wagner T, Stoppa-Lyonnet D, Fleischmann E, et al. Denaturing highperformance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics. 1999;62:369–376.

    Article  PubMed  CAS  Google Scholar 

  26. Buzin CH, wen CY, nguyen VQ, et al. Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic. Biotechniques. 2000;28:746–750, 752–753.

    PubMed  CAS  Google Scholar 

  27. Nakagawa H, Hampel H, de la Chapelle A. Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat. 2003;22:258–263.

    Article  PubMed  Google Scholar 

  28. Hendrickson BC, Pruss D, Lyon E, Scholl T. Application of haplotype pair analysis for the identification of hemizygous loci. J Med Genet. 2003;40:346–347.

    Article  PubMed  CAS  Google Scholar 

  29. Hogervorst FB, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 1995;10:208–212.

    Article  PubMed  CAS  Google Scholar 

  30. Hardy CA. The protein truncation test. Methods Mol Biol. 2002;187:87–108.

    PubMed  CAS  Google Scholar 

  31. Eng C, Brody LC, Wagner TM, et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet. 2001;38:824–833.

    Article  PubMed  CAS  Google Scholar 

  32. Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet. 1999;105:72–78.

    Article  PubMed  CAS  Google Scholar 

  33. Rubinstein WS, O’Neill SM, Peters JA, Rittmeyer LJ, Stadler MP. Mathematical modeling for breast cancer risk assessment: state of the art and role in medicine. Oncology (Huntington). 2002;16:1082–1094.

    Google Scholar 

  34. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol. 2001;21:1–18.

    Article  PubMed  CAS  Google Scholar 

  35. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–689.

    Article  PubMed  CAS  Google Scholar 

  36. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701–2712.

    Article  PubMed  CAS  Google Scholar 

  37. Puget N, Torchard D, Serova-Sinilnikova OM, et al. A 1-kb Alumediated germ-line deletion removing BRCA1 exon 17. Cancer Res. 1997;57:828–831.

    PubMed  CAS  Google Scholar 

  38. Puget N, Stoppa-Lyonnet D, Sinilnikova OM, et al. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res. 1999;59:455–461.

    PubMed  CAS  Google Scholar 

  39. Puget N, Gad S, Perrin-Vidoz L, et al. Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. Am J Hum Genet. 2002;70:858–865.

    Article  PubMed  CAS  Google Scholar 

  40. The BRCA1 Exon 13 Duplication Screening Group. The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 2000;67(1):207–212.

    Article  Google Scholar 

  41. Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997;17:341–345.

    Article  PubMed  CAS  Google Scholar 

  42. Unger MA, Nathanson KL, Calzone K, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000;67:841–850.

    Article  PubMed  CAS  Google Scholar 

  43. Hendrickson B, Deffenbaugh AM, Gaglio CA, et al. Prevalence results for five recurrent BRCA1 rearrangement mutations in 7570 analyses. Am J Hum Genet. 2003;73(5):487.

    Google Scholar 

  44. Frolov A, Prowse AH, Vanderveer L, Bove B, Wu H, Godwin AK. DNA array-based method for detection of large rearrangements in the BRCA1 gene. Genes Chromosomes Cancer. 2002;35:232–241.

    Article  PubMed  CAS  Google Scholar 

  45. Gad S, Scheuner MT, Pages-Berhouet S, et al. Identification of a large rearrangement of the BRCA1 gene using colour bar code on combed DNA in an American breast/ovarian cancer family previously studied by direct sequencing. J Med Genet. 2001;38:388–392.

    Article  PubMed  CAS  Google Scholar 

  46. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997;60:1013–1020.

    PubMed  CAS  Google Scholar 

  47. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–187.

    Article  PubMed  CAS  Google Scholar 

  48. Kauff ND, Perez-Segura P, Robson ME, et al. Incidence of nonfounder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002;39:611–614.

    Article  PubMed  CAS  Google Scholar 

  49. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60:1079–1084.

    PubMed  CAS  Google Scholar 

  50. Moller P, Heimdal K, Apold J, et al. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer. 2001;37:2428–2434.

    Article  PubMed  CAS  Google Scholar 

  51. Einbeigi Z, Bergman A, Kindblom LG, et al. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer. 2001;37:1904–1909.

    Article  PubMed  CAS  Google Scholar 

  52. Menkiszak J, Gronwald J, Gorski B, et al. Hereditary ovarian cancer in Poland. Int J Cancer. 2003;106:942–945.

    Article  PubMed  CAS  Google Scholar 

  53. Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C. Breast cancer genetics in African Americans. Cancer. 2003;97(suppl):236–245.

    Article  PubMed  CAS  Google Scholar 

  54. Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL. Characterization of common BRCA1 and BRCA2 variants. Genet Test. 2002;6:119–121.

    Article  PubMed  CAS  Google Scholar 

  55. Fleming MA, Potter JD, Ramirez CJ, Ostrander GK, Ostrander EA. Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc Natl Acad Sci U S A. 2003;100:1151–1156.

    Article  PubMed  CAS  Google Scholar 

  56. Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test. 2002;6:107–113.

    Article  PubMed  Google Scholar 

  57. Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol. 2003;21:740–753.

    Article  PubMed  Google Scholar 

  58. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer. 2002;2:113–123.

    Article  PubMed  Google Scholar 

  59. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646.

    Article  PubMed  CAS  Google Scholar 

  60. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260–1268.

    Article  PubMed  Google Scholar 

  61. Muhr D, Wagner T, Oefner PJ. Polymerase chain reaction fidelity and denaturing high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;782:105–110.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Evanston Northwestern Healthcare Center for Medical Genetics, Northwestern University Feinberg School of Medicine, Evanston, IL, 60201, USA

    Wendy S. Rubenstein MD, PhD, FACMG (Medical Director and Assistant Professor)

  2. Department of Medicine, Northwestern University Feinberg School of Medicine, Evanston, IL, 60201, USA

    Wendy S. Rubenstein MD, PhD, FACMG (Medical Director and Assistant Professor)

Authors
  1. Wendy S. Rubenstein MD, PhD, FACMG
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, 10021, USA

    Debra G. B. Leonard MD, PhD (Professor and Vice Chair for Laboratory Medicine) (Professor and Vice Chair for Laboratory Medicine)

  2. Hematology, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Adam Bagg MD (Director) (Director)

  3. Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, 30322, USA

    Angela M. Caliendo MD, PhD (Vice Chair and Associate Professor) (Vice Chair and Associate Professor)

  4. Northwestern University Feinberg School of Medicine, Evanston, IL, 60201

    Karen L. Kaul MD, PhD (Professor) (Professor)

  5. Department of Pathology and Laboratory Medicine, Evanston Northwestern Healthcare, Evanston, IL, 60201, USA

    Karen L. Kaul MD, PhD (Professor) (Professor)

  6. Molecular Pathology Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System, Philadelphia, PA, 19104, USA

    Vivianna M. Van Deerlin MD, PhD (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Rubenstein, W.S. (2007). Inherited Breast Cancer. In: Leonard, D.G.B., Bagg, A., Caliendo, A.M., Kaul, K.L., Van Deerlin, V.M. (eds) Molecular Pathology in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-0-387-33227-7_17

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-33227-7_17

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-33226-0

  • Online ISBN: 978-0-387-33227-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation